3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Precise Poly(ADP-ribose) Polymerase Modulation

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with an IC50 of ~50 nM in CHO cells, enabling >95% PARP inhibition at ≥1 μM without significant cytotoxicity (Grunewald et al., 2019). The compound improves endothelial function following oxidative stress by enhancing nitric oxide-mediated vasorelaxation. In diabetic db/db mouse models, it reduces mesangial expansion and podocyte depletion, supporting its utility in diabetic nephropathy research. 3-Aminobenzamide exhibits high aqueous and organic solvent solubility and is stable at -20°C. Sourced from APExBIO, it is intended exclusively for research use (product page).

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosyltransferases involved in DNA repair, cell death regulation, and innate immunity. Humans encode 17 PARP isoforms, four of which (PARP1, PARP2, PARP5a, PARP5b) catalyze poly-ADP-ribosylation (PARylation) (Grunewald et al., 2019). PARP activation is triggered by DNA strand breaks and oxidative stress, leading to NAD⁺ depletion and cell dysfunction if uncontrolled. Excessive PARP activity is implicated in ischemia-reperfusion injury, diabetic complications, and inflammatory responses.

Pharmacological inhibition of PARP, as achieved with 3-Aminobenzamide, enables experimental dissection of ADP-ribosylation processes, provides a tool for controlling cell death pathways, and offers a model for understanding PARP’s role in disease pathophysiology (see related article).

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide competitively inhibits the NAD⁺-binding site of PARP enzymes. This prevents transfer of ADP-ribose units to target proteins, thereby blocking poly(ADP-ribosyl)ation. The compound exhibits nanomolar potency (IC50 ~50 nM in CHO cells) (APExBIO). At concentrations above 1 μM, it achieves >95% PARP inhibition with minimal off-target toxicity. The inhibition is reversible and does not directly alter the DNA damage response but instead modulates downstream cellular events. In models of reperfusion injury, 3-Aminobenzamide prevents oxidant-induced myocyte dysfunction by limiting NAD⁺ consumption and subsequent cellular energy failure (in-depth mechanism review).

Evidence & Benchmarks

• In CHO cells, 3-Aminobenzamide inhibits PARP activity with an IC50 of ~50 nM, providing robust inhibition at ≥1 μM without significant cytotoxicity (Grunewald et al., 2019).
• In oxidative stress models, the compound restores acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation after H₂O₂ treatment (APExBIO product documentation).
• In db/db diabetic mouse models, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte depletion, key markers of diabetic nephropathy (see Chempaign.net).
• PARP inhibition by 3-Aminobenzamide enhances virus replication in primary macrophages infected with macrodomain-mutant coronaviruses, confirming the critical regulatory role of PARPs in antiviral responses (Grunewald et al., 2019).
• No significant cytotoxic effects observed at concentrations up to 1 mM in standard viability assays (lab workflow article).

This article expands upon previous summaries by integrating new evidence on diabetic nephropathy and antiviral innate immunity, clarifying the selectivity and safety profile of 3-Aminobenzamide (compare with protocol-focused review).

Applications, Limits & Misconceptions

3-Aminobenzamide (PARP-IN-1) is widely used in:

• PARP activity inhibition assays in mammalian cell models.
• Studies of DNA repair, apoptosis, and cell survival after oxidative or genotoxic stress.
• Vascular research, especially for endothelium-dependent vasorelaxation following ROS insult.
• Preclinical models of diabetic nephropathy, where it modulates albumin excretion and glomerular injury.
• Innate immunity investigations, particularly in viral infection models with altered ADP-ribosylation dynamics.

However, several boundaries and misconceptions exist:

Common Pitfalls or Misconceptions

• 3-Aminobenzamide is not selective for individual PARP isoforms and may affect multiple family members.
• It is not suitable for in vivo diagnostic or therapeutic use; intended exclusively for research applications (APExBIO).
• Long-term solution storage is not recommended due to chemical instability.
• At high concentrations, off-target effects may occur, requiring careful dose titration.
• Results from cell models may not directly extrapolate to complex in vivo systems without additional validation.

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1; SKU: A4161) is available as a solid, molecular weight 136.15, chemical formula C₇H₈N₂O, CAS 3544-24-9 (product page). Solubility profiles: ≥23.45 mg/mL in water (ultrasonic assistance), ≥48.1 mg/mL in ethanol (ultrasonic assistance), and ≥7.35 mg/mL in DMSO. Store at -20°C for maximum stability; ship on Blue Ice. For in vitro assays, typical working concentrations range from 50 nM to 1 mM, with >95% PARP inhibition achieved at ≥1 μM in CHO cells. Solution preparation should be freshly performed prior to use for optimal reproducibility. For detailed protocols on cell viability, proliferation, and cytotoxicity workflows, see this scenario-driven guide. Compared to earlier protocol articles, this dossier integrates cross-model benchmarks and addresses storage, shipping, and off-target risk in greater detail.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) remains a gold-standard tool for dissecting poly(ADP-ribose) polymerase function across diverse research models. Its nanomolar potency, broad solubility, and well-characterized safety profile support its application in oxidative stress, vascular biology, and diabetic nephropathy studies. Future research may clarify isoform-specific effects and expand its use in viral immunity models. Researchers are encouraged to source high-purity 3-Aminobenzamide directly from APExBIO and consult the A4161 product page for technical details and regulatory guidance.